The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluating results from the multiple myeloma subset of patients treated with denosumab or zoledronic acid (ZA) in a randomized phase III study.
Noopur S. Raje
Consultant or Advisory Role - Celgene; Millennium; Novartis; Onyx
Research Funding - Acetylon Pharmaceuticals; Amgen; Lilly
Wolfgang Willenbacher
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Vania Hungria
No relevant relationships to disclose
Andrew Spencer
No relevant relationships to disclose
Yulia Alexeeva
No relevant relationships to disclose
Thierry Facon
Consultant or Advisory Role - Amgen
A. Keith Stewart
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Novartis
David Roodman
Consultant or Advisory Role - Amgen
Evangelos Terpos
Consultant or Advisory Role - Amgen
Honoraria - Amgen; Novartis
Amy Feng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Ada Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Arun Balakumaran
Employment or Leadership Position - Amgen
Stock Ownership - Amgen